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INTRODUCTION : 
 
 
Though the incidence of rectal cancer in the world and in India is low it is 
gradually increasing. Outcomes of rectal cancer has improved significantly since 
the evolution of TME and ConcurentChemoradiation.We now see a local control 
rates decreased  from 20 % to less than 5 % and 5 year overall survival of 62.3% 
to 69.2%(1) While increasing number of patients are long time survivors their 
quality of life specifically related to anal dysfunction is of great concern. Organ 
preservation and organ sparing techniques of managing cancers is of utmost 
importance for such long term survivors.Some anatomical sites like Head and 
neck cancers and prostate cancers have shown promising outcomes in quality of 
life with such techniques. 
 
Anal sphincter sparing attempts have been made by surgeons in some low rectal 
cancer patients. However a proactive approach by radiation oncologists towards 
anal sphincter sparing radiation techniques has been lacking. Few authors have 
reported the dose to anal sphincter and correlated with anal dysfunction in 
patients undergoing radiation therapy for prostate cancer which is usually given 
upto a mean dose of 70 Gy(1)However there is currently very little information 
on anal dysfunction in high or mid rectal cancerpatient undergoing 
chemoradiation followed by low anterior resection.Hence this study was 
undertaken to develop a contouring method ,evaluate the 
dosimetriccharacteristics of anal sphincter and correlate the anal manometric 
changes with the anal sphincter dose. 
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4 
 
AIMS : 
 
 
To assess the relation of anal manometry changes and radiation dose to anal 
 
spinchter. 
 
 
OBJECTIVES : 
 
 
1. To generate dose volume histogram for anal sphincter  
 
2. To study the relation of anal manometry gradient changes and radiation 
dose to anal sphincter  
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REVIEW OF LITERATURE 
 
 
EPIDEMIOLOGY 
 
 
Cancer is one of the major non communicable disease worldwide (2). Cancer 
isone of the leading cause of morbidity and mortality with approximately 14 
million new patients and 8.2 million deaths in 2012(3).Colorectal cancersare one 
of themost common cancers in the world. World Health Organisation estimates 
9,45,000 new cases and 492 000 deaths annually. Rectal cancer is more common 
in the developed countries (4). 70% arise in the colon and 30% occur in the 
rectum(5). 
 
FIGURE 1 SHOWS THE DISTRIBUTION OF MOST COMMONLY  
DIAGNOSED CANCERS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Most of the studies consider colon and rectal cancer as a single entity. Rectal 
cancer follows a different natural disease course compared to carcinoma colon(6) . 
Physical inactivity, obesity, diet low in fruits and vegetables and smoking are 
considered risk factors (7). Rectal cancer has male preponderance(7). Biological 
7 
 
and gender linked factors may play a role (8). Colorectal cancer has a disease- 
specific mortality rate of approximately 33% in developed countries(9). There is 
increased incidence of rectal cancer in Asian countries probably due to adoption of 
Western lifestyle(10). 
 
SCENARIO IN INDIA 
 
 
In India, incidence of the colorectal cancer is low. According to the registries, 
rectal cancer is higher in the rural region(11). India has diversity in cultural and 
diet practices. Incidence varies among the regions (3). Chennai registry showed 
the highest while Ahmedabad showed the lowest(7). The incidence of rectal 
cancer was 5.5 to 1.6/100,000 among men while women ranges 2.8 to 0/100,000 
among women. One interesting observation wasthat there were many younger 
with rectal cancer(12). High rates in young Indians suggests different 
etiopathogenesis. The absolute number of cancer patients in India rising because 
of increasing population and improved life expectancy. 
 
Initiation of screening programmes may bring change in trends (13). Bringing 
such programme is big challenge. Effort has to be made to bring health awareness 
among the public. According to one study, physician recommendation plays a role 
in screening behavior in all countries. Before implementing mass screening 
programs, awareness has to be raised and promoting the physicians‘ participationis 
necessary(10).Problems faced by India are affordability , adequate 
healthpersonnel, and sociocultural barriers to cancer control(2) 
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ETIOLOGY - RISK AND GENETIC FACTORS 
 
 
Obesity is considered as a risk factorand increase the risk of CRC by 19%. (7). 
Cereals, fruits, vegetables are considered to have chemopreventive properties 
whilegood and routine physical activity reduces this risk by 24% (14). Role of 
lifestyle remains an area of research. 
 
Fish consumption leads to reduced risk(9). Benefit is attributed to omega3 and 
omega 6 polyunsaturated fatty acids. Risk is reduced upto 12%. Effect is more on 
rectal cancer than colon cancer. 
 
One study from Tata Memorial hospital showed no significant risk for chewers, 
smokers and alcohol drinkers compared to those without the habits. 
 
Cabbage-eaters had 50% reduction in risk compared to those who did not eat 
cabbage. Fresh fish eaters has a 40–70% reduction in risk is seen when compared 
to those who did not eat fresh-fish. Dark-green-leafy-vegetables did not have 
protective effect(15). Some nondietary risk factors are genetic predisposition, 
tobacco smoking and ulcerative colitis.. 
 
ANATOMY OF RECTUM 
 
 
The terminal portion of digestive tract is rectum .It originates from cloaca(16)and 
starts at the rectosigmoid junction ending at the level of levatorani(17). This 
formed by pelvic rectum measuring around 12-15 cm length, formed from the 
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primary intestine , covered by mesorectum and the anal canal,3-4 cm length. 
These corresponds to the sphincters,. They are formed from the ectoderm(18). 
 
Rectum is classified into upper one third (12–16 cm), middle one third (6–12cm), 
and lower third (within 6 cm) from the anal verge. 
 
Rectum supports the fecal matter and initiates the urge to defecate(19).Antero 
laterallyupper third of the rectum is covered by the visceral peritoneum. Middle 
third is covered by the peritoneum in front  while the lower third of the rectum is 
extraperitoneal.It is bordered anteriorly by the Denonvilliers fascia and the 
presacral fascia is continuous with Waldeyer fascia posteriorly (19). 
 
 
Rectum is supplied by superior hemorrhoidal artery. It is a branch of inferior 
mesenteric artery. and supplies upper two thirds..The distal 1/3 of the rectum is 
supplied by middle hemorrhoidal artery which is a branch of internal iliac artery. 
 
 
Superior rectal vein drains into inferior mesenteric vein and from thereinto the 
portal circulation. Middle rectal vein drains to the internal iliac vein andthereafter 
into inferior vena cava. Upper two-thirds of the rectum drains along the superior 
hemorrhoidal artery then inferior mesenteric nodes followed by para-aortic nodes. 
Lower one-third of rectum supplies the nodal basin along the internal iliac artery. 
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ANATOMY OF ANAL SPHINCTER 
 
 
Anal sphincter surrounds anal canal.,is bent forward. and  averages around 5 cm . 
Anal canal consists of dentate line and is covered by the internal anal sphincter 
and external anal sphincter(17). Anal sphincter consists of multiplelayers .It is 
made up of anal lining (innermost ), internal sphincter and outer striated muscle 
layer(20). External sphincter consists of three parts-subcutaneous, superficial and 
deep part. 
 
Functioning of the anal sphincter is carried out by rich supply of sensory endings 
near the dentate line and proprioceptive fibres. Anal lining consists of colonic 
mucosa on top and lowest part made by (keratinized) squamous epithelium. 
 
INTERNAL ANAL SPHINCTER: 
 
 
This smoothmuscle sphincter is continuation of muscularispropria. The important 
role is maintaining the anal sphincter rest pressure. It does not extend till lower 
part of anal sphincter. Muscular part is made up of external anal sphincter. 
 
Internal sphincter is supplied by sympathetic fibres and parasympathetic fibres, It 
is carried through the inferior pelvic plexus and splanchnic nerves (S2–S4).The 
afferent impulses pass through the parasympathetic nerves and the pain impulsesis 
carried through sympathetic and parasympathetic nerves. Space between internal 
and external anal sphincter is called as inter sphincteric space. It consists 
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Of longitudinal muscle of rectumwhich is nothing but part of puborectalis 
(puboanalis) and part of levatorani. 
 
Internal anal sphincteris a ring like structure surrounding approximately2.5– 4.0 
cm of the anal canal. The inferior border is in touch with but separated from 
external anal sphincter. 
 
Its action is entirely involuntary. It is in a state of continuous maximal contraction. 
It helps the external anal sphincter to close the anal opening and helps in the 
defecation.. 
 
Sympathetic fibers from the superior rectal and hypogastric plexuses initiate and 
control internal anal sphincter contraction. Its contraction is prevented by 
parasympathetic fibers. Sphincter is tonically contracted for most of the time to 
avoid leakage of gas or fluid. It is relaxed upon distention of the rectal ampulla 
which requires voluntary contraction of the puborectalis and external anal 
sphincter. 
 
The internal anal sphincter is not innervated by the pudendal nerve. Pudendal 
nerve supplies motor and sensory supplying external anal sphincter(21). 
 
Internal anal sphincter does contribute 55% of the resting pressure of the anal 
canal, important for bowel continence (mainly liquid and gas). 
 
When the rectum fills beyond a certain amount, rectal walls are distended, initiates 
defecation cycle. It begins with the rectoanal inhibitory reflex, where the internal 
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anal sphincter relaxes. It allows a small amount of rectal contents to descend into 
the anal canal. Anal mucosa checks whether it is gas, liquid or solid. Any 
interference with the internal anal sphincter present as varying degrees of 
fecalincontinence (mainly incontinence to liquid) or mucous discharge. 
 
EXTERNAL ANAL SPHINCTER: 
 
 
This is astriated muscle whichcontrols tones voluntarily.They are made up of slow 
twitch fibreswhich are capable of prolonged contraction.Theyare flat planeof 
muscular fibers, elliptical, andtightly attached to the covering surrounding anus. 
They measure about 8 to 10 cm in length, in anterior to its posteriorextremity. 
They measure about 2.5 cm opposite the anus at the time of defecation occurs as 
sphincter muscle pulls back(22). 
 
They are supplied by a nerve from inferior rectal branch of pudendal  nerveand 
perineal branch of the fourth sacral nerve. 
 
External sphincter consists of three segments. 
 
 
1. Subcutaneous: Surrounding the lowermost portion of canal.  
 
 
2. Superficial part is situated above the subcutaneous part. It is attached to perineal 
body and coccyx. Superficial part consists of main portion of the muscle, arising  
 
from anococcygeal  raphe.  Itstretches  from  the  tip  of  coccyx to  the  
posteriormargin of the anus.. 
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3. Deep part is continuous with the superficial division, surrounding the uppermost 
portion of the canal and they are associated with the puborectalis posteriorly. 
Deeper portion forming a complete sphincter to the anal canal.Theirfibres closely 
surrounds to internal anal sphincter, 
 
They are supplied by inferior rectal nerves and by perineal branch of the fourth 
sacral nerve. This muscle is in variable tonic contraction during waking hours, and 
it can be contracted voluntarily. Main function is to postpone defecation .and 
contributing to anal resting tone(20). 
 
The action of this muscle is characteristic.. 
 
 
(1) They are always in a state of tonic contraction. They have no opposite acting 
muscle to keeps the anal canal and orifice closed.  
 
(2) They can be put into a condition of greater contraction voluntarily to close the 
anal opening., (3) They help in fixing the central point of the perineum.  
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FIGURE 2 a& 2b SHOWS THE RELATION OF ANAL SPHINCTER WITH OTHER 
SURROUNDING STRUCTURES IN LATERAL VIEW AND ANTEROPOSTERIOR VIEW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 a 
Figure 2 b 
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PHYSIOLOGY OF DEFECATION: 
 
 
MECHANISM OF CONTINENCE : 
 
 
Functional and compliant rectum or neorectum is essential for the continence. 
Maintenance of compliant rectum depends on competent anal sphincter 
mechanism. During filling of rectum, sensation of rectal contents are felt. Filling 
further produces temporary defaecatory sensation, followed by constant urge, and 
then pelvic discomfort . This is called as maximal tolerable volume. 
 
There are variations among the individuals in the maximal tolerable and sensation 
volumes. Maximal tolerable volume ranges between 130 to 500 ml, being no 
difference between males and females. But rectal pressures during filling tend to 
be lesser in females(23). 
 
Rectal motility is periodic, segmental, occurs as either solitary contractions or as 
chain of periodic pressure waves . Span of those cycles can range from one minute 
to several minutes. 
 
The main function of puborectalis muscle is contributing to maintenance of the 
anorectal angle producing a ―flap valve effect. 
 
Resting pressure is contributed by external anal sphincter and  responsible for 
most  of  the  pressure  during  squeeze.  In  normal  subjects,  maximal  squeeze 
pressure ranging between 90 to 360 cm H2O(24).Maximal squeeze pressure in 
normal females was found to be decreased after the fourth decade. They may be 
16 
 
due to decreased function of the pudendal nerves, partial atrophy of external anal 
sphincter muscle due to estrogen depletion(25). Mass movements through 
peristalsis pushes the fecal materials from sigmoid colon torectum. This results in 
distension of rectal wall stimulating stretch receptors, thereby initiating defecation 
reflex , thus rectum is emptied. .Stretch receptors are present in the puborectalis 
muscle. Stretch receptors sends sensory impulses to sacral spinal cord. Motor 
impulses travels through parasympathetic nerves to the sigmoid colon and rectum, 
finally into anus.Ifdefaecation is socially convenient, relaxation of levatorani, 
external anal sphincter and puborectalis occurs. (25) 
 
Relaxation of these muscles and sinking of pelvic floor during straining raises the 
anorectal angle. Voluntary contractions of the abdominal muscles and 
diaphragmhelps in defecation by enhancing the pressure inside abdomen , thereby 
pushing the wall of sigmoid colon and rectum inward. The rigidity of opening anal 
sphincter is at least thrice greater in the starting phase of opening in comparison to 
opening of the anal canal to 1 to 2cm in diameter(25) 
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STAGING (TNM)AJCC SEVENTH EDITION 
 
 
 
 
TABLE 1 SHOWS THE TNM STAGING 
 
 
 
 
T – PRIMARY  
TUMOR  
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis Carcinoma in situ: intraepithelial or invasion of lamina 
 propria 
T1 Tumor invades submucosa 
T2 Tumor invades muscularispropria 
T3 Tumor invades subserosa or into non – 
 peritonealizedpericolic or perirectal tissues 
T4 T4a – Tumor perforates visceral peritoneum 
 T4b- tumor directly invades other organs or structures 
 
 
 
 
 
N – REGIONAL LYMPH 
 
NODES 
 
Nx Regional lymph nodes cannot be assessed 
 
N0 No regional lymph node metastasis 
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N1 N1a- Metastasis in 1 regional lymph node 
 N1b- Metastasis in 2-3 regional lymph node 
 N1c- Tumor deposits i.e satellites , in the 
 subserosa , or in non-peritonealisedpericolic or 
 perirectal soft tissue without regional lymph 
 node metastasis 
N2 N2a- Metastasis in 4-6 regional lymph nodes 
 N2b- Metastasis in 7 or more regional lymph 
 nodes 
 
 
 
 
 
M – DISTANT 
 
METASTASIS 
 
M0 No distant metastasis 
 
M1 M1a – metastasis confined to one organ 
 
(liver,lung, ovary, non regional lymph nodes) 
 
M1b – Metastasis to more than one organ or the 
 
peritoneum 
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MANAGEMENT OF RECTAL CANCER 
 
 
Management of rectal cancer depends on disease stage at diagnosis based on 
which patients are classified into high, intermediate, or low risk. Prognostic and 
predictive markers can be applied for optimal risk stratification and subsequent 
treatment. These markers can be histopathological,determined with imaging and 
havebiomolecular background. Till now, none of the markers has been found to be 
of significance and independent value .Recent advances in imaging techniques and 
biomolecular research promises considerable potential. Over the past years, 
advances in multimodality treatment strategies have added (25) significance to 
outcome in rectal cancer patients (26)(27)(28)(29)(30). Treatment decisions are 
based on tumor-node-metastasis classification and circumferential resection 
margin at time of diagnosis. Rectal cancers are divided into : Good,‖  2.Bad,‖  and 
Ugly.‖ (31). 
 
Every group requires different approach based on the risk of disease metastasis. 
Implementation of group-specific prognostic markers and predictive markers 
besides the TNM staging may simplify the treatment decision process. The 
introduction of the total mesorectal excision technique decreased local recurrence 
rates in rectal cancer patients from more than 20 per cent to around 10 per 
cent.(32) . 
 
Addition of preoperative radiotherapy (RT) with or without chemotherapy has a 
beneficial effect on local control and, sphincter preservation is possible in some  
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 19 % of cases (33)(34)(35)(36). True survival benefit of the addition of 
chemotherapy in the preoperative setting remains unproven. (26). But the 
treatment is associated with significant acute and long-term toxicity and even 
mortality (37)(38)(39). Besides decrease in local recurrences, distant metastases 
predominate with incidences around 30% for locally advanced rectal cancers (40). 
Thus optimal treatment of rectal cancer is aimed at prevention of both local and 
distant tumor recurrence and in addition minimizing the risk of side effects due to 
overtreatment. 
 
Rectal cancer acts different course unlike colonic tumors(5). Surgical approach, 
local recurrence rates and associated complications of early stage rectal tumors are 
recognizably different from colonic cancer. This paved the way to develop 
different specific protocols for rectal cancer. Advances in imaging modality like 
MRI for staging and preoperative chemoirradiation led to clearly defined 
improvement in outcomes for the patient. 
 
Good rectal cancers are early stage (T1 or T2), negative lymph nodes rectal 
cancers that, after (TME) surgery, have very low risk of local recurrence rates and 
high cure rates(29). More controversial treatment options like rectum preservation 
with or without preoperative chemoradio therapy (CRT) or chemoirradiation 
followed by a wait-and-see policy are considered for such patients (41). 
 
Lymph node involvement cannot be reliedon magnetic resonance imaging (MRI) 
alone. (42). Unfortunately, the majority of early rectal cancer patients do not meet 
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these criteria. For patients with relatively small tumors (T1-3) and where risk of 
lymph node involvement exceeding more than 6%, treatment with preoperative 
chemo irradiation therapy followed by surgery for the primary tumor might,  be an 
option. 
 
A challenging approach in this type of tumors is the watch-and-wait  policy as 
propounded by Habr-Gama et al(43). After chemoirradiation, patients with a 
clinically complete response are closely followed up. The first reports looked 
promising with a 5-year disease-free survival rate of 95% and an overall survival 
(OS) rate of 100% in the case of a clinical complete remission. The downside is 
that,  only25% to 50% of the patients achieving a clinically complete response will 
have a true pathological complete response (pCR) (44). 
 
Bad or intermediate-risk rectal cancer patients consists of large T3N0 tumors or 
T1-3N1 tumor and will be treated with preoperative radiation therapy followed by 
total mesorectal excision surgery .In the case of a threatened and/or involved 
mesorectal fascia, they are treated with preoperative chemo irradiation. The option 
of choosing between preoperative long course chemo irradiation and short-course 
radiation therapy is still a debatable topic. 
 
Two randomized studies compared preoperative long course chemo irradiation 
therapy with short course radiation. The downside of the studies were 
underpowered to evaluate the effect on local control (45)(46). Early complications 
were less frequent in the short course radiation group. There were no differences 
22 
 
neither in late complications nor in quality of life between the 2 groups. Ugly 
tumors have a very high risk of local and distant recurrence rates They have 
features like advanced (T4) stage and advanced lymph node involvement. 
 
Survival improvement may be achieved by response-assessed treatment adaptation 
and the addition of targeted therapies with radio sensitizing potential. 
 
Few strategies use epidermal growth factor receptor inhibitors, such as cetuximab, 
and inhibitors of the vascular endothelial growth factor, such as bevacizumab 
(47).The results of phase I-II trials with cetuximab have been not very good with 
pCR rates of ranging only 5% to 10%, suggesting a below additive interaction 
between chemoirradiation and cetuximab. The efficacy of bevacizumab has been 
proven in metastatic colorectal cancer. The first results of the addition of 
bevacuzimab to chemoirradiation in patients with rectal cancer are encouraging, 
showing a trend toward improved 5-year overall survival (95% vs 81% in those 
not receiving bevacuzimab) and disease free survival (69% vs 55%) and 
pathological complete rates of around 15%. Results of further prospective 
randomized trials required to be evaluate. Problems such as heterogeneous 
responses and tumor resistance have to be overcome. 
 
Local recurrence rate of rectal cancer varies 6% to 10% .The number needed to 
treat with preoperative radiation therapy to prevent one local recurrence does vary 
around 10 to 18 patients. Only a subgroup of patients with good tumors has an LR 
risk of less than4%. Limited treatment in these patients seems justified. The local 
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recurrence risks of bad and ugly tumors ranges around 8% and 20%, depending on 
T,N, and circumferential resection margin involvement. Predicting these tumor 
characteristics will help us to identify the specific patient groups and thereby 
select them for suitable treatment in the future(26). 
 
Actual distance of the tumor to the mesorectal fascia has consistently shown to be 
a important factor for local recurrence because T-stage cannot differentiate 
between tumors that can be safely resected and those with a high chance of 
circumferential resection margin involvement. MRI has been the imagingmodality 
of choice found useful for the predictingthe circumferential resection 
margin..Studies have shown sensitivity varying from around 60% and 88% and 
specificity is between 73% and 100%(27). 
 
Lymph node involvement showedno significant difference between the different 
imaging modalities like EUS, computed tomography scan, or MRI has been 
shown.(28). Sensitivity was between 55% - 67% with specificities ranging74% - 
78%. Studies suggest that have shown detection of lymph node metastases can be 
better with use of additional MRI criteriasuch as extracapsular extension of 
disease and signal difference.. 
 
HISTOPATHOLOGY EVALUATION : 
 
Local tumor extent is designated through the pathologic T-staging , with T3 and 
T4 tumors are shown to have highest risk of local recurrence. Nodal involvement 
and CRM involvement are well reliable by histopathology. Lympho vascular 
invasion, poorly differentiation , serosal involvement and extramural venous 
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invasion, are the factors considered to have increased local recurrence risk(29).  
Depth of extramural disease and extramural venous invasion are found to be good 
associations with nodal involvement.(30).They can be used to determine the extent 
of response to chemoirradiation.. 
 
PREDICTIVE MARKERS:  
Tumor stage and grade were not good enough of predicting response to 
treatment.(31). Prediction of treatment response with imaging techniques 
nowadays shows encouraging results(32). But staging accuracy is decreased after 
preoperative treatment compared to untreated cases. This may be secondary to 
post radiation edema,fibrosis, necrosis or inflammation.(33).  
 
MERCURY trial found the prognostic relevance of MRI after neo adjuvanttreatment. 
MRI-assessed tumor regression grade after preoperative therapy found better overall 
and disease free survival in responders compared to non responders. Results for ‗T‘ 
stage were consistent, with accuracy of MRI staged T-stage of 79% after 
treatment(34)(35). This study showed that amount of tumor replacement by fibrosis 
related better with survival than T-stage after chemoirradiation.(36). 
 
 
STAGING PREOPERATIVELY: 
 
 
This has two purposes. It helps in surgical planning by defining anatomy and 
determining prognosis(6). Assessment of features by histopathologists in the 
resected rectal specimen remains the well defined method of prognostification. 
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Those features areassessment of depth of spread, nodal disease, extramural  
vascular invasion (EMVi), circumferential resection margin and perforation of 
peritoneum. 
 
 
 
PROGNOSTIC FEATURES : 
 
1. T STAGE: 
 
Multiple histopathological studies have found T3 tumors with 5 mm of extramural 
invasion have a cancer specific 5-year survival rate of around 54% and more than 
85% when the depth is 5 mm or lesser(37). There fore the identification of high 
risk patients with an extramural tumor spread of 5-mm depth of extramural tumor 
invasion directs the treatment. Spread of tumor into the perirectal fat causes 
increase in nodal involvement. Depth of extramural spread is very important factor 
in determining the prognosis and directing election of patients for preoperative 
treatment. . 
 
LYMPH NODAL INVOLVEMENT : 
 
Dukes‘ et al showed the best relationship between depth of spread beyond the 
muscular is propria and the risk of involvement of lymph node(38). Lymph node 
positivity is an independent worse prognostic factor, and is more pressed when 4 
or more lymph nodes are involved. Low burden of nodal involvement (N1) with a 
total mesorectal excision was not associated with an increased risk of pelvic 
recurrence(39).  
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CIRCUMFERENTIAL RESECTION MARGIN : 
 
It is an important prognostic factor in the assessment of rectal cancer.. CRM 
positivity is a poor prognostic factor for survival, with 40% of patients prone to 
develop distant metastases, and almost double the risk of dying(40).Identification 
and aggressive treatment of potentially CRM-positive patients is  the key in 
preventing unwanted pelvic recurrence. . 
 
EXTRAMURAL VENOUS INVASION: 
 
Tumoral extramural invasion is an predictor of both local and distant failures. 
 
 
 
 
PERITONEAL INVOLVEMENT: 
 
Peritoneal involvement can be defined as tumor present at the peritoneal surface‘ 
or tumor cells found to be free in peritoneum and proof of adjacent ―ulceration. 
 
Local peritoneal involvement points to considerable prognostic implications, 
predicting for local recurrence. This is an important cause of pelvic failure. But the 
prevention and treatment of peritoneal perforation by the primary tumor is not 
specifically addressed in clinical trials. 
 
Staging for all rectal cancer patients should include chest x-ray Computed 
tomography of the abdomen and pelvis.. Complete colonic examination by 
colonoscopy should be carried out before treatment, if possible. Serum CEA 
should be checked preoperatively(41).   
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Those patients should undergo MRI pelvis to assess T and N categories and the 
circumferential resection margin. Axial, coronal and sagittal T2-weighted images 
of the pelvis and high-resolution (HR)T2-weighted sequences using phased-array 
coil are required. Use of the phase-array coil MRI and the development of T2-
weighted fast-spin sequences have made thin-section MRI to delineate rectal 
tumors This allows accurate determination of prognostic 
 
features as well as anatomic assessment of the pelvis. There is overlap in size 
between normal, reactive nodes and those containing a tumor. Size is not 
advocated as a reliable way of checking the involvement of lymph nodes. By 
identifying mixed intranodal signal and/or irregular border, it can assess lymph 
node involvement with 85%accuracy(42) .A negative MRI scan of lymph nodes is 
insufficient evidence as imaging techniques cannotidentify micro metastases 
inside lymph nodes. Patients with stage IIor III rectal cancer should be offered 
preoperative therapy. Restaging MRI after preoperative chemo radiation is 
optional. No recommendation can be made to support orrefuse the regular use of 
restaging MRI after neo adjuvant therapy. Restaging MRI may be appropriate 
where there is suspected MRF involvement or when a complete response would 
change management,  asper patient basis(41).  
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SURGERY: 
Goal of surgery is to decrease risk of not to leave behind gross disease and 
decreasing local recurrence and also preserving the function of sphincter ,sexual 
and urinary functions(6). Varieties of surgical options are available depending  on 
the location of tumor, stage and  the possibility of sphincter preservation. 
 
Some local procedures aretransanal local excision, endoscopic microsurgery and 
trans abdominal resection (anterior resection) with colorectal anastomosis, 
proctectomy with total mesorectal excision and colo-anal anastomosis / abdomino 
perineal resection with a definitive colostomy(6). Isolated pelvic recurrence was 
the disadvantage of surgery. In late 1970‘s new procedure called total mesorectal 
excision was developed and the number of recurrences decreased 
significantly.(43). Removing the mesorectum ,eliminated the foci of 
adenocarcinoma , which was found several centimeters away to lower edge of 
rectal cancer(43). In anterior resection much of the tissue remains in the pelvis. 
Total mesorectal excision by itself decreased local relapse to lesser than 5%(44). 
 
Then importance focused on circumferential resection margin(CRM)(45). . 
 
 
It was found to be related to survival and delivered a better prognostic 
representation(45). Larger the distance of the tumor from the CRM, the better the 
prognosis. When tumor cells are upto the resection margin (0 mm), worst 
prognosiswas observed.(46). There were fewer local recurrences when the margin 
was more than 1 mm (0.4%)(47). 
29 
 
 
There are six distinct types of margin involvement. Those are 
 
 
1. Direct tumor spread (29%),  
 
 
2. Discontinuous tumor spread (14% to 67%),  
 
 
3. Lymph node metastases (12% to 14%),  
 
 
4. Venous invasion (14% to 57%),  
 
 
5. Lymphatic invasion (9%), and  
 
 
6. Perineural tumor spread (7% to 14%)(48).  
 
 
 In around 30% of patients, it was found that tumor showed more than one method 
of involvement(46). 
 
Advanced stage, (46), ulcerative and stenosing pattern of growth, (49), infiltrative 
margin(48), poorly differentiated tumors(50) , vascular invasion(49), these factors 
have more the chance of margin involvement. Studies have shown more positive 
margins in tumors situated in the lower rectum when compared to upper and 
middle rectum tumors. This is due to the difference in surgical technique exercised 
and also a difficult local anatomy to access surgically(51). It is a very strong 
indicator of local recurrence even in the time of neoadjuvant therapy. They also 
behave as marker of tumor reduction(45). 
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Anterior resection is offered for tumors in the upper and middle thirds of the 
rectum .This can also be done in low rectal tumors without involvement of the 
sphincter. 
 
From the oncology perspective margin of around 5 cm is required from the distal 
end of the tumor for higher tumors. After neoadjuvant treatment, even 1- 2 cm 
margins are considered acceptable for very low lying tumors, .It allows 
sphincter-preservation. APR is indicated with definitive colostomy when the 
distal margins are not safe or it will lead to incontinence.(6). 
 
ROLE OF RADIATION THERAPY 
 
 
Rectal cancer is well known for local recurrence. Role of radiation therapy is 
strongly proved in the palliative setting of locally relapsing disease (52). The 
above finding led to the research of its value in preoperative and postoperative 
conditions. Radiotherapy was added to surgery in management of patients with 
resectable rectal cancer either before surgery (53)(54)(55)(56)(57)(58) or after 
surgery(59)(60). 
 
Upto mid-1990s,post operative radiation therapy was practiced as standard of 
care.(61).Many studies showed that there was decrease in the local recurrence 
but no improvement in overall survival(62). 
 
Studies in lab and in animals proved the adding fluorouracil as concurrent 
therapy increased the local efficiency of radiation(63)(64).. From there, post 
operative radiation therapy with or without chemotherapy has been used to 
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improve outcomes(61). It showed good local control and overall survival as 
compared with surgery alone or surgery plus irradiation(62)(52).But these 
regimens used methyl-CCNU, risk factor for acute non lymphocytic leukemia 
 
GITSG and NCCTG showed methyl-CCNU does not produce any benefit to 
radiation plus 5Fluorouracil(65)(66).Therefore methyl-CCNU became obsolete. 
 
Preoperative irradiation was considered as very dose-effective than postoperative 
radiotherapy. Higher doses are required if radiation is indicated after surgery to 
reduce the local recurrence(67). 
 
Enthusiasmarose in preoperative chemo radiotherapy setting for patients with 
resectable rectal cancer. This was based on the expected survival benefit 
achieved  
There are   many   potential   advantages   like   administering both   
agents 
preoperatively(68). Benefits are good compliance , down-staging , increase the 
chance of cure with surgery, allowing sphincter preservation, radio biologically 
better tumor oxygenation and decreased side effects.. No survival benefit seen 
when compared preoperative with postoperative chemoradiotherapy. 
 
But Preoperative treatment (chemoradiotherapy) is associated with better overall 
compliance rate, better local control, reduced side effects and more sphincter 
preservation in patients with distal rectal tumors(68). 
 
Multiple  studies  have  shown  lesser  rates  of  local  failure  with  preoperative 
radiotherapy compared with surgery alone. Swedish Rectal Cancer Trial assessed  
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a short course of preoperative irradiation (25 Gy delivered in five fractions) and 
found there is advantage in overall survival(69). This is the first trial showed that 
there is survival advantage after pelvic radiotherapy alone either given 
preoperatively or postoperatively(70). 
Introduction of total mesorectal excision questioned the benefit of preoperative 
therapy to optimal surgery .A study done by Kapite inproved that there is 
decrease in local recurrence from 8.2% to 2.4% by adding preoperative radiation 
to total mesorectal excision .(71). Significant complication was perineal wound 
dehiscence. 
 
PREOPERATIVE RADIATION  THERAPY  AND  LOW  ANTERIOR 
RESECTION : 
In patients with resectable rectal cancer, enthusiasm arose in sphincter 
preservation. Advantage of preoperative therapy is to reduce the volume of 
primary tumor. If the tumor is located very close to the dentate line, the decrease 
in volume allows the surgeon to doa sphincter preserving procedure. . One harm 
of preoperative therapyis that we may over treat patients who may not require 
therapy, like very early stages T1-2N0ordistant metastatic disease. When 
sphincter preservation is considered, it should be offered to patients in whom 
disease can be resected safe from oncological point of view. 
Total radiation dose of 45 to 50.4 Gyat 1.80 Gy per fraction, one fraction per day 
is offered. Surgery should be scheduled one to one and half month later to allow 
down staging of tumor and patient recovers the side effects of radiation and 
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chemo therapy. Alternative approach is short course radiation therapy consisting 
of 25 Gy in five fractions followed by surgery next week. 
 
LATE SIDE EFFECTS AFTER RADIATION THERAPY: 
 
Late toxicity are those which arises from 3 months after radiation therapy 
treatment. Better cure rates in the treatment led to understanding of survivorship 
issues. Radiotherapy dosimetric factors, like dose per fraction irradiation site, 
total dose, volume irradiated, and dose heterogeneity shown influence on 
development of late radiation toxicity. So we should know the incidence of 
radiation morbidity. Surgery and radiation therapy has detrimental effect on the 
quality of patient. 
 
Late side effects are bowel frequency and urgency, and fecal incontinence. (43). 
Decrease in the anorectal function has been seen when compared with post 
operative radiation therapy vs surgery alone.(72). There is very minimal data on 
the quality of life in rectal cancer survivors(73). radiation therapy had detriment 
effect on social function and fecal incontinence. 
 
Symptoms which commonly occur after low anterior resection are increased 
frequency , urgency to defecate, and soiling . These shows loss of the ability of 
the rectal reservoir and these symptoms constitute anterior resection syndrome. 
 
Approximately 60% of patients experience some degree of incontinence and 
around 33% feel urgency and frequency regularly. 
Anorectal dysfunction after surgery mainly because of capacity intolerance. One 
study by Nesbakken showed anal resting and squeeze pressure and volume of 
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rectal sensibility were not changed after operation. effect of preserved anal 
sphincteron was seen well in patients who underwent low anterior resection(74). 
. It showed neorectal capacity was reduced. 
 
One study by Lane et al showed that reflexes of anal sphincter preserved after 
sphincter preserving surgery(75) 
Frequency of fecal incontinence was 25% after radiotherapy vs. 11% with 
surgery-only in studies involving short course radiation therapy. One trialfrom 
Poland has compared short-course preoperative radiotherapy with long-course 
chemo-radiotherapy. They found no difference in the frequency of fecal 
incontinence. These patients experienced poor social function and global quality 
of life. This study did not comment on dose deposition to normal tissue. 
 
ANAL SPHINCTER AND RADIATION THERAPY: 
Sphincter without function is more harmful than not having it .Well functioning 
colostomy is better. Effect on anal sphincter is worse seen with radiation therapy 
administered after surgery than before surgery. A study by Birnbaum et al, 
assessed short-term and long-term effect of preoperative radiation therapy on 
sphincter function. Heassessed them objectively with anal manometry with or 
without transrectal ultrasound. He found radiation therapy had very less effect on 
sphincter function(76)(77). One study by Marjinen et al showed short course 
treatment led to more sexual dysfunction, passive improvement of bowel 
activities, and reduced daily activity after surgery. But they did not affect health 
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related QOL(78) 
 
 
Considerable amount of cecum, ileum , sigmoid colon , rectum and anal 
sphincter is involved in the treatment. Acute effects are because of death of large 
number of cells in tissues with rapid multiplication.Late effects occur in those 
tissues which has slow proliferation. These changes will not manifest till it enters 
the next cycle of cell division. Once it starts , injury because of radiation will 
manifest. 
WHY IT IS DIFFICULT TO MEASURE LATE BOWEL 
DYSFUNCTION: 
Most patients after follow up for five years are discharged. They get treated 
elsewhere if they develop any further complications . The oncologist may not 
know about this. Young patients survive long to get this complication while elder 
patients may not. 
We should rule out any existing abnormal bowel function before starting 
treatment 
When patients who underwent pelvic radiation therapy, presents with the 
complaints of gastrointestinal symptoms, most of them attribute to radiation. 
After thorough investigation about one-third have symptoms arising from an 
unrelated cause(79).  
Radiation oncologist rely on questionnaires to find out the radiation toxicity 
36 
 
which may be misleading. This is because of either practical difficulties ,patient 
refusing the socially stigmatized words or patients may feel the symptom is not 
worth the time spending with doctor. When they report, there is no good support 
system to help them out. There is no much awareness among the patient and 
oncology community about the late effects. Lack of basic mechanism and studies 
aids for it. Therefore specific questionnaires are difficult practically. . 
FAECAL INCONTINENCE: 
Faecal incontinence affects almost half of patients with normal preoperative 
functioning sphincters(80). It may range from unintentional gas release to minor 
soiling or complete escape of rectal contents(81). This leads to avoidance of 
activities like long-distance travel, avoiding places where bathroom facilities are 
not available. 
It is the result of failure of more than one component of the continence 
mechanism. The rectum, the anal sphincters, and the pelvic floor muscles are 
important in this continent mechanism(82). Rectum behaves like reservoir to 
store stool. Neorectum after low anterior resection has a lesser capacity thereby 
causing a decrease in maximum tolerance volumes. 
Anal sphincters are supplied by neural fibers, branches and bundles, formed by 
pudendal nerve, pelvic splanchnic nerves and hypogastric nerves , which in turn  
forms pelvic plexus. They allow voluntary contraction of the sphincter through 
somatic impulsation. They also control complex autonomic anorectal reflexes. 
Anal canal has nerve endings which are sensitive to pain, temperature, and touch, 
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which differentiates solid or liquid stool from flatus. This allows for selective 
passage of flatus. 
Radiotherapy decreases this amenability of the rectum due to fibrosis. It results 
in reduced reservoir function. Fibrosis of the myenteric plexus of the internal 
anal sphincter secondary to radiation therapy can prevent closing of the anal 
opening in a resting state. 
Radiation injury to pelvic floor also causes fecal incontinence by damaging the 
levator ani and disturbances in the anorectal angle. 
 
Initially improvement in anorectal function seen around six to twelve months. 
This is because of expansion in the storing capacity of the neorectum. This is 
evident from from post-operative assessment of function after one year which 
showed many patients attained continence to solid stool. Only control of minor 
staining, flatus, and stool frequency is more variable(83). Worsening of faecal 
incontinence over time is mainly present in patients who underwent pelvic 
radiotherapy. This is secondary to radiation injury to endovascular cushions. 
Endovascular cushions aids in continence at rest(84). 
 
Nerve-sparing surgery can be difficult because of the anatomical variations in the 
nerve patterns and accurate identification of those structures. These nerves are at 
risk of diathermy secondary to blood loss and hemostasis. nerve-stimulating 
device may be useful in these conditions. (85). (71). 
Earlier having a stoma was considered a negative impact on quality of life. But 
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those patients who underwent low anterior resection experience anorectal 
dysfunction fare poorly in the quality of life scores, (86). (87). How et al showed 
this relation was better associated with all domains of questionnaire(88). 
Cultural, social, religious, and socio demographic factors can play a role in 
decision of having a stoma. 
 
Managing patients with incontinence after rectal cancer treatment are still not 
known.. No good evidence to support the effectiveness any treatment. 
Conservative measures are aimed at symptomatic control like dietary regiments, 
absorbent pads, and pharmacotherapy like hormonal manipulation, constipating 
agents, and enemas.. Colonic irrigation in the morning  to clean the colon has 
shown to relieve symptoms(89). Non-surgical procedures available are 
biofeedback and pelvic floor muscle training. 
Biofeedback therapy helping the patients how to use the pelvic floor muscles 
properly, is recommended. This  helps  in   rectal  sensitivity,  strength,  and  
coordination training(90).  Pelvic  floor  muscle  training  improves  pelvic  floor  
support.  It  is considered as standard of care   for urinary incontinence   It   
improves faecal incontinence too . This may not be benefical in patients whose 
pelvic floor and its nerve supply are damaged by surgery. If conservative 
management fails, surgical intervention can be considered. Cause has to be 
identified. Anorectal physiology is assessed with manometry. mechanical 
damage to the sphincter muscle assessed by endoanal ultrasound. 
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Sacral nerve stimulation can be done if there is intact sphincter..But the 
experience with sacral nerve stimulation is not sufficient (91). 
If there is defective sphincter, artificial bowel has to be constructed. But there is 
a risk of complications due to previous injury. This is reported in few 
studies(92). So this should be an last measure(93).  
 
ANAL MANOMETRY AND FECAL INCONTINENCE : 
Birnbaun et al assessed the acute effect of preoperative radiation on anal 
function. He found that radiation therapy before surgery has minimal immediate 
effect over the anal sphincter. It may not be a considerable factor for 
incontinence after sphincter preservation (76). 
 
Pollack et al assessed late effects of short-course radiotherapy on anorectal 
function. He assessed the patients their quality-of-life with questionnaires, 
clinical examination, anorectal manometry, and endoanal ultrasound for a period 
of 14 years. He found that short-course radiotherapy, interferes in anorectal 
function and increases bowel symptoms permanently.(94).  
 
Canda studied the acute and long term effects of preoperative chemoradiotherapy 
on anorectal function and quality of life of the patients. He found that 
considerable decrease in the resting and squeeze pressures immediately after the 
completion of preoperative chemoradiotherapy This finding was significant to 
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the patient group who underwent surgery group alone. They were assessed post 
operatively(95). Much of the studies are done in prostate cancer patients in 
relating the dose received by anal sphincter and fecal incontinence. Alsadius et al 
suggested mean dose to anal sphincter more than 40 Gy associated with higher 
incidence of fecal incontinence(96). In another study Al-Abany et al showed 
there is increased risk of fecal leakage for a mean absorbed dose of more than 
46Gy to the anal-sphincter(97). They also suggested whether more than 35 Gy to 
less than 60% of volume or more than 40 Gy to less than 40% volume of the 
anal-sphincter can provide any benefit is not known. 
 
DELINEATION OF  CLINICAL  TARGET  VOLUME   IN  RECTAL 
CANCER: 
Correct definition andproper delineation of the clinical target volume is required 
to avoid under dosage of regions that can possibly have cancer cells. There are 
five subsites for local recurrence: 
1. Mesorectalsubsite 
2. Posterior pelvic subsite ,  
3. Lateral pelvic subsite ,  
4. Inferior pelvic subsite , and  
5. Anterior pelvic subsite  
Mesorectal subsite comprises mesorectum, which is defined as the adipose tissue 
with lymph, vascular and nerve structures, surrounded by a fascia. . Mesorectum 
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is cylindrical, with cone-shaped in cranial and caudal direction, arising at the 
level of the sacral promontory where superior rectal artery arises and ends at the 
level where levatorani muscle inserts into rectal wall. 
 
 
Posterior pelvic subsite (PPS) comprises of presacral space. It is a triangular 
region, surrounded behind by the presacral fascia (Waldeyer‘s fascia) and in 
front by mesorectal fascia. This structure is well seen on magnetic resonance 
imaging ., It contains median sacral vesses ,lateral sacral vessels, lymphatics of 
presacralchains, anterior branches of sacral nerves, and inferior hypogastric 
plexus. 
 
Lateral pelvic subsite consists of area on the lateral side of the mesorectal fascia 
and the lateral pelvic side walls. 
Inferior pelvic subsite : It consists of anal triangle of the perineum, consists of 
the anal sphincter complex with perianal and ischiorectal space. 
Anterior pelvic subsite (APS) has all pelvic organs that are located in front of 
mesorectal subsite. 
Lymph node regions: 
Five lymph node regions were found to be significant with the lymphatic 
drainage pathway of the rectum.  
Mesorectal lymph node group is the mesorectal tissue surrounded by the 
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mesorectalfascia, containsmesorectal nodes with their vessels and lymph nodes 
along with superior rectal artery. Lymph nodal group surrounds lymphatic tissue 
along the inferior mesenteric artery upwards. Lymphatic spread to the lateral 
lymph nodal regions is involvement of the lymph nodes along the middle rectal, 
the obturator, and the internal iliac vessels. Clinical target volume : It encompass 
1.tumor, 2.mesorectal subsite , and the 3.posterior pelvic subsite in all cases. 
Inferior pelvic subsite is considered to be at risk when the tumor is located 
within 6 cm from the anal margin, or (2) the tumor reaching anal sphincter and 
an Abdomino perineal resection is planned. 
In all patients, mesorectal nodes and lateral lymph node regions Have to be 
considered. Obturator nodes are included if the tumor is located less than10 
cmfrom the anal margin. External iliac nodes are considered only when there is 
involvement of anterior organs. 
TECHNICAL ASPECTS OF IMAGE BASED TREATMENT PLANNING: 
Modern radiation treatment planning are very much advanced. We can provide a 
very high dose to a certain region while sparing the nearby structures. There are 
not many studies on the sphincter sparing radiation therapy like parotid and 
constrictor sparing in head and neck tumors. 
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MATERIALS AND METHODS 
1.  STUDY DESIGN 
This study was conducted in Department of Radiotherapy, Christian Medical 
College (CMC). Patients who were diagnosed to have rectal cancer and planned 
for low anterior resection were included in this study. 
 
Inclusion criteria: 
 Locally advanced rectal cancer-clinical or radiological evidence of T3/T4 
or N1,N2 
 Adenocarcinoma histology 
 Being considered for neo adjuvant radiotherapy(conformal Radiation 
therapy) along withconcurrent chemotherapy (Capecitabine) 
 No prior pelvic malignancies 
 No history of prior radiation to the abdomen/pelvis 
 Not a known case of myelodysplastic syndrome/myelofibrosis 
Exclusion criteria 
 Low rectum tumors, not amenable for low anterior resection 
 Metastatic disease 
The proposed study was presented in the Institutional Review Board (IRB) which 
includes Research committee and Ethics Committee and approval was obtained 
(copy enclosed). The patients were selected based on the inclusion and exclusion 
criteria. 
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DETAILED ALGORITHM: 
 
LOCALLY ADVANCED CARCINOMA RECTUM PATIENTS SCREENED 
 
 
ELIGIBILTY  
1.ADENOCARCINOMA RECTUM (HIGH AND MID)  
2. NON METASTATIC   
3. PATIENTS PLANNED FOR LONG COURSE CHEMOIRRADIATION THERAPY FOLLOWED BY LOW   
ANTERIOR RESECTION IN MULTIDISCIPLINARY TUMOR BOARD 
 
 
 
 
 
 
ANAL MANOMETRY WAS DONE IN SURGERY OPD BY A TECHNICIAN BEFORE STARTING RADIATION THERAPY 
 
 
 
IMMOBILISATION WAS CARRIED OUT WITH VACLOC AND HEEL LOCK AND KNEE SUPPORT (FOR SOME) WITH 
PATIENTS HAND ABOVE THE HEAD AND TATTOOED AT SUPRAPUBIC LEVEL 
 
 
 
PLANNING CT SCAN WITH RT MARKERS SLICE THICKNESS – 5 mm EXTENT – FROM DIAPHRAGM TO MID 
THIGH WITH IV CONTRAST AND WITHOUT CONTRAST (FOR FEW PATIENTS) 
 
 
 
CT SCAN IMAGES WERE TRANSFERRED TO TREATMENT PLANING SYSTEM (TPS)- ECLIPSE 
 
 
 
CONTOURING WAS DONE AS PER STANDARD GUIDELINES- TARGET – GTV, CTV & PTV ORGAN AT RISKS – BLADDER, 
FEMORAL HEADS 
 
 
 
ANAL SPHINCTER WAS CONTOURED WITH THE HELP OF RADIOLOGIST 
 
 
 
DISEASE RESPONSE WILL BE REASSESSED AFTER 6 WEEKS AS A PART OF TREATMENT 
 
 
 
ANAL MANOMETRY WAS DONE BEFORE SURGERY 
 
 
 
THIS WILL BE DONE FOR ALL PATIENTS WHO WERE INCLUDED PROSPECTIVELY 
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ANAL MANOMETRY: 
 
 
Anal manometry was done as outpatient procedure using Dyno 3000software 
(Biomedica) by a trained technician. This procedure requires 5-10 minutes without 
the need of anesthesia or any premedications. To obtain measurement a tube was 
inserted in the anal canal approximately 3cm , 2 cm and 1 cm from anal verge. At 
each length the resting pressure and squeeze pressure was measured by asking the 
patient to be in a relaxed position and try to squeeze sphincter respectively. 
 
 
 
ANAL SPHINCTER DELINEATION: 
 
Since there are no established guidelines for anal sphincter delineation ,it was 
done with the help of radiologist. Initially the puborectalis sling was identified on 
the CT scan and then subsequently the whole of puborectalis sling, internal anal 
sphincter and external anal sphincter was contoured. The cranial extent was from 
where the puborectalis sling was visualized and the caudal extent was where the 
external anal muscle became visible. 
 
 
 
SAMPLE SIZE: 
 
This study group consisted of 5 patients prospectively and 16 patients 
retrospectively treated with conformal radiation therapy in radiation therapy 
department between January 2013 till July 2015. 
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Only 5 patients were able to recruit prospectively . An amendment was made , 
requesting IRB board to allow to take retrospective data who underwent low 
anterior resection. Planning CT images were choosen and  the anal sphincter was 
contoured with the help of radiologist and dose to anal sphincter was calculated 
using Plato and Eclipse treatment planning systems. 16 patients were taken 
retrospectively from the year 2013 January –till February 2015. 
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RESULTS 
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RESULTS: 
 
 
21 patients were selected who underwent conformal radiation therapy and planned 
for low anterior resection between the period of January 2013- July 2015. 14/21 
patients were treated with 3D conformal radiation therapy and 7/14 were treated 
with intensity modulation radiation therapy. 
 
 
 
All of them underwent long course chemoirradiation and were administered 
concurrent chemotherapy with capecitabine(825mg/m2 twice daily). No 
chemotherapy was administered for patients who underwent short course radiation 
therapy. 
 
 
 
PATIENT CHARACTERISTICS: 
 
There were 11(52.4%) Male and 10(47.6%))female patients. Most of the tumors 
were in mid rectum 13(62%)) followed by upper third 7(33.3%)). One patient was 
found to have growth in low rectum . He was planned for intersphincteric low 
anterior resection and underwent the same. Most of the patients were locally 
advanced stage and  the commonest histology reported was moderately 
differentiated adenocarcinoma. 
 
 
Most commonly received a dose of was 50.4 Gy in 28 fractions. Few patients who 
underwent intensity modulated radiation therapy received simultaneous integrated 
boost. 2/21 patients underwent short course radiation therapy and they received 25  
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Gy in 5 fractions. 7/21 patients underwent intensity modulated radiation therapy 
and 14/21 underwent 3D conformal radiation therapy. Most of the tumors showed 
good response as evident by down staging of T and N. Most of the patients 
tolerated the treatment well and very few had a break in radiation therapy. The 
commonest reasons was grade 2 radiation enteritis. Two patients had break in 
chemotherapy. First patient had mild elevation of transaminases which normalized 
soon and another patient had low counts. 
 
In this study, we found the mean dose of anal sphincter was 28.77 Gy. 
PATIENT CHARACTERISTICS 
Table No: 1 PATIENT CHARACTERISTICS 
 
Variables Numbers 
  
Age(years) Mean -49.33 (Range : 20-83) 
  
Sex – male 11 
 Female 10 
Marital status-  
Married 18 
Unmarried 3 
Location of growth  
1. Upper 7 
2. Middle 13 
3. Lower 1 
Pre op T stage  
1. T1 0 
2. T2 2 
3. T3 16 
4. T4 3 
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Pre op N stage  
 
1.N0 2 
 
2.N1 2 
 
3.N2 17 
 
Post op T stage  
 
1.T0 1 
 
2.T1 4 
 
3.T2 3 
 
4.T3 10 
 
5.T4 0 
 
Post op N stage  
 
1.N0 13 
 
2.N1 4 
 
3.N2 1 
 
Biopsy  
 
1. Moderately differentiated  
 
adenocarcinoma 14 
 
2. Well differentiated  
 
adenocarcinoma 3   
 
3. Poorly differentiated 
3  
adenocarcinoma   
 
4. Focus of adenocarcinoma 1  
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TABLE 2 DOSIMETRIC CHARACTERISTICS 
 
 
 
 
 
 
 
 
Variables Mean 
Std. 
Minimum Maximum  
Deviation      
 
     
 
95% prescribed dose 
97.5% 1.68 94% 99%  
covered ---of PTV Phase 1      
 
     
 
D95  phase 2 97.7% 1.35 95% 99.9% 
 
     
 
Mean dose to anal sphincter 28.77 Gy 12.49 8.95 Gy 49.95 Gy 
 
     
 
Length of anal sphincter 4.36 cm 1.43 2.5 cm 8 cm 
 
     
 
Volume of anal sphincter 29.35 cc 11.82 13.56cc 67.9cc 
 
     
 
OARS     
 
     
 
Bowel bag Volume reciving 
113.82cc 79 24.9cc 302cc  
45Gy      
 
     
 
Bladder     
 
Dose received by 35% of 42.88 Gy 6.68 24 Gy 50.7 Gy 
 
volume     
 
Right femur     
 
Dose received by 25% of the 25.9 Gy 4.46 14Gy 35.8Gy 
 
volume     
 
Right femur     
 
Dose received by 40% of the 23.25 Gy 4.62 12.5 Gy 32.96 Gy 
 
volume     
 
Left femur     
 
Dose received by 25% of the 26.02 Gy 5.66 14 Gy 35.8 Gy 
 
volume     
 
Left femur     
 
Dose received by 40% of the 23.56 Gy 4.89 12.5 Gy 32.96 Gy 
 
volume     
 
Overall treatment time 
39.74 3.09 34 46  
(Days)      
 
     
 
53 
 
 
 
 
 
FIGURE 3DISTRIBUTION OF MALES AND FEMALES  
PATIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4 DISTRIBUTION OF MARITAL STATUS  
AMONG PATIENTS 
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FIGURE 5 DISTRIBUTION OF LOCATION OF  
THE GROWTH IN OUR STUDY PATIENTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6 DISTRIBUTION OF  T STAGE PREOPERATIVELY 
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FIGURE 7 DISTRIBUTION OF N STAGE  
PREOPERATIVELY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 8 DISTRIBUTION OF BIOPSY(MOST COMMON BEING 
MODERATELY DIFFERENTIATED ADENOCARCINOMA) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
56 
 
FIGURE 9 . DISTRIBUTION OF PATIENTS WHO EXPERINCED BREAK  
IN RADIATION THERAPY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 10. DISTRIBUTION OF PATIENTS WHO EXPERIENCED 
BREAKIN CHEMOTHERAPY 
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FIGURE 11 BELOW FIGURE SHOWS DIFFERENT DOSE  
PRESCRIPTION TO PTV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 12. DISTRIBUTION OF TECHNIQUE INVOLVED  
(IMRT AND 3DCRT) 
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FIGURE 13. DISTRIBUTION OF PATIENTS WITH ypT STAGE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 14DISTRIBUTION OF PATIENTS  
WITH yp N STAGE 
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FIGURE 15 COMPARISON OF ‗T‘ STAGE BETWEEN  
PREOPERATIVELY AND POSTOPERATIVELY 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ypT stage 
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 FIGURE 16- COMPARISON OF PREOPERATIVE AND               
                  POSTOPERATIVE N STAGE  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ypN stage 
 
 
 
A preliminary anal sphincter delineation method was established in consultation 
with a senior radiologist with expertise in Pelvic imaging. The subsequent anal 
sphincter delineations undertaken by the PI were checked and verified by the 
guide and radiologist. 
 
The mean dose to anal sphincter was 28.77 Gy. The mean volume of anal 
sphincter was 29.35cc and the mean length of the anal sphincter was 4.36 cm. 
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There was no correlation between the mean dose of anal sphincter and volume of 
anal sphincter. There is definite corelation between dose received by the anal 
sphincter and distance between them from to midpoints of GTV, CTV and PTV. 
Higher the distances, there is definite decrease in the mean dose to anal sphincter. 
 
 
 
Out of the 5 patient recruited to undergo manometric study only 3 patient‘s 
preradiation and post radiation manometric readings were documented. Of the two 
missing reading one patient was lost for follow up and another patient‘s post 
radiation measurement was missed. The pre radiation resting and squeeze pressure 
for patient 1,2,3 was 91.4 mm Hg and 158.8, mmHg,77.2 and 141.7 mmHg , 67.5 
and 147 mmHg and the post radiation pressure was 78 and 140 mmHg, 67 and 125 
mmHg, 65 and 140 mmHg respectively. 
 
 
 
Since it was a very small sample size for detecting the pressure change and mean 
dose to anal sphincter, we were unable to document clinically relevant or 
statistically significant correlation between any result.. 
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Dose to planning target volume achieved good coverage (more than 95 percent of 
the prescription dose) and the constraints to organ at risks like bowel bag, femoral 
heads and bladder  wereachieved as per QUANTEC guidelines. 
 
 
 
FIGURE 17 THE RELATION BETWEEN THE MEAN DOSE OF ANAL 
SPHINCTER(x axis) AND VOLUME OF ANAL SPHINCTER(Y axis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VOLUME OF  
ANAL SPHINCTER 
(cc) 
 
 
 
 
 
 
 
 
 
 
 
 
MEAN DOSE TO ANAL SPHINCTER  (Gy) 
 
 
 
The correlation between mean dose to anal sphincter and volume of anal was -
0.18, however it was not statistically significant (p=0.483). 
 
 
 
 
 
63 
 
 
 
FIGURE 18 RELATION BETWEEN MEAN DOSE TO ANAL 
SPHINCTER (x axis) AND DISTANCE OF MID POINT OF ANAL 
SPHINCTER TO INFERIOR BORDER OF GTV (y axis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISTANCE  
FROM THE  
MID POINT OF  
ANAL  
SPHINCTER TO  
INFERIOR  
BORDER OF  
GTV (mm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEAN DOSE TO ANAL SPHINCTER  (Gy) 
 
 
 
 
 
 
 
The correlation between mean dose to analsphincter  andGTV was -0.694, 
which was statistically significant (p=0.001). 
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FIGURE 19 RELATION BETWEEN MEAN DOSE TO ANAL 
SPHINCTER (x axis) AND DISTANCE OF MID POINT OF ANAL 
SPHINCTER TO INFERIOR BORDER OF CTV PHASE 1(y axis) 
 
 
 
 
 
 
 
 
 
 
 
 
DISTANCE FROM  
THE MID POINT  
OF ANAL  
SPHINCTER TO  
INFERIOR  
BORDER OF CTV  
PHASE-1 (mm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEAN DOSE TO ANAL SPHINCTER  (Gy) 
 
 
 
 
 
 
 
 
The correlation between mean dose to anal canal and ctvph1 was -0.708, which 
was  statistically significant (p=0.001). 
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FIGURE 20 RELATION BETWEEN MEAN DOSE TO ANAL SPHINCTER (x 
axis) AND DISTANCE OF MID POINT OF ANAL SPHINCTER TO INFERIOR 
BORDER OF CTV PHASE 2 (y axis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISTANCE FROM  
THE MID POINT OF  
ANAL SPHINCTER  
TO INFERIOR  
BORDER OF CTV  
PHASE-2 (mm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEAN DOSE TO ANAL SPHINCTER  (Gy) 
 
 
 
 
 
The correlation between mean dose to  anal sphincter and PTV Phase 2was 
-0.792, which was statistically significant (p=0.000). 
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FIGURE 21  RELATION BETWEEN MEAN DOSE TO ANAL 
SPHINCTER (x axis) AND DISTANCE OF MID POINT OF ANAL 
SPHINCTER TO INFERIOR BORDER OF PTV PHASE 1 (y axis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISTANCE FROM  
THE MID POINT  
OF ANAL  
SPHINCTER TO  
INFERIOR  
BORDER OF PTV  
PHASE-1 (mm) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEAN DOSE TO ANAL SPHINCTER  (Gy) 
 
 
 
 
 
The correlation between mean dose to anal sphincter and PTV phase 1was -0.858, 
which was  statistically significant (p=0.000). 
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FIGURE 22  RELATION BETWEEN MEAN DOSE TO ANAL 
SPHINCTER (x axis) AND DISTANCE OF MID POINT OF ANAL 
SPHINCTER TO INFERIOR BORDER OF PTV PHASE 2 (y axis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISTANCE FROM  
THE MID POINT OF  
ANAL SPHINCTER  
TO INFERIOR  
BORDER OF PTV 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEAN DOSE TO ANAL SPHINCTER  (Gy) 
 
 
 
 
 
 
The correlation between mean dose to analsphincter  and phase 2 PTV was -
0.716, which was  statistically significant (p=0.003). 
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FIGURE 23 THE RELATION BETWEEN INDIVIDUAL PATIENT (X AXIS)) AND 
MEAN DOSE RECEIVED BY ANAL SPHINCTER in Gy (Y axis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MEAN DOSE TO  
ANAL  
SPHINCTER(Gy) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PATIENT ID 
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FIGURE 24 PTV PHASE 1 ANTERO POSTERIOR VIEW 
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FIGURE 25 PTV PHASE-2 IN ANTEROPOSTERIOR  
VIEW 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
71 
 
FIGURE 26 DIAGRAM SHOWS PUBORECTALIS SLING (CRANIAL 
CUT WHERE ANAL SPHINCTER WAS CONTOURED) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
72 
 
FIGURE 27 DIAGRAM SHOWS CONTOUR OF ANAL SPHINCTER  
DELINEATION BY US 
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FIGURE 28 DIAGRAM SHOWS ANAL SPHINCTER IN AP VIEW 
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FIGURE 2 SHOWS ANAL SPHINCTER IN LATERAL VIEW 
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DISCUSSION 
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DISCUSSION: 
 
 
While Outcomes of rectal cancer has improved significantly since the evolution of 
TME and Concurent Chemoradiation., the quality of life in survivors specifically 
related to anal dysfunction is of great concern. Few authors have reported the dose 
to anal sphincter and correlated with anal dysfunction in patients undergoing 
radiation therapy for prostate cancer which is usually given upto a mean dose of 
70 Gy(1). However there is currently very little information on anal dysfunction in 
high or mid rectal cancer patient undergoing chemoradiation followed by low 
anterior resection. 
 
This study was undertaken to develop a preliminary delineation guideline for anal 
sphincter and evaluate the correlation of dose to anal dysfunction. In our study, to 
evaluate anal manometry, we were able to measure in only 3 patients 
prospectively owing to time constraint and strict inclusion criteria which was a 
major limitation of our study. So we were unable to conclude regarding correlation 
between manometry changes and dose received by anal sphincter. 
 
The injury caused by by the radiation to the sphincter muscle appears to be a 
secondary factorsince 10%-60% of patients with anal sphincter dysfunction are 
accompanied by urinary and sexual disorders (hyperactive bladder, urine 
incontinence, urine retention, impotence, lack of ejaculation, lack of orgasm), 
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pointing towards a most probable neurological etiology of the disorder. Isolated 
fecal incontinence after radiotherapy is rather rare. 
 
Each of the manometric pressures is composed of several elements. Voluntary 
squeeze pressure, determined mostly by the external sphincter‘s ability to contract 
in response to somatic impulsation, said to be less important in the Anterior 
Resection pathogenesis. Basal sphincter pressure consists of pressures generated 
by the internal anal sphincter (approx. 40-60%), external anal sphincter (about 20-
50%) , and hemorrhoidal cushions, Three components are involved. They are 
autonomic and somatic innervation and anatomical structures within the anal 
canal. Rectal examination and anoscopy can exclude anatomical disturbances of 
the anal canal as causes of lower basal pressure, but the influence of both 
neurological systems yet to be explored. There is only little evidence that radiation 
causes damage to pelvic floor and muscles. 
 
Better understanding of muscle damage and dysfunction following radiation 
therapy will improve pelvic floor rehabilitation possibly, preventing detrimental 
impact(98). 
 
Reducing the dose to anal sphincter may be important to reduce the risk of long 
term fecal leakage. There are lack of standards in reporting adverse events, both 
patient and clinician, in trials .It raises a number of questions about how future 
treatment can be optimized on the basis of past results. 
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We suggest that it may be worthy to consider the anal sphincter region as an 
organ-at- risk when irradiating tumors in the pelvis. We may be able to use 
technological advances in imaging and delivery of radiation to avoid fecal leakage 
in future survivors from cancer in the pelvis who have been cured by radiotherapy. 
 
In this study, we found that the mean dose to anal sphincter was 28.77 Gy which 
was similar to the doses reported by Chen et al(2). According to few studies done 
in prostate cancer survivors, showed that the mean dose to anal sphincter more 
than 40 Gy is associated with higher incidences of fecal leakage. Doses less than 
40 Gy is associated with less chance of fecal leakage(3). This shows that type of 
surgery and the surgeons skills may play a role in causing the fecal incontinence , 
probably due to injury during the procedure to the nerve structures supplying 
sphincter muscles. 
There are not enough studies on the dosimetry of anal sphincter, anal sphincter 
delineation, relation dose received by anal sphincter and risk of developing fecal 
continence. Since developing fecal incontinence is late effect of pelvic radiation 
therapy, we suggest all the patients coming to our clinics have to be assessed with 
a locally validated questionnaire. Questionnaire, contouring anal sphincter as 
routine organ at risk (OAR),checking the pressure with anal manometry serially 
needs to be standardized. A neurophysiological study like (EMG) of anal sphincter 
will be desirable to objectively document the sphincter function. This will help us 
in evaluating and recommending the radiation dose constraint for anal sphincter. 
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CONCLUSION 
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CONCLUSION: 
 
 
The mean dose to Anal sphincter was 28.77 Gy which was way below the 
threshold dose  implicated in radiation induced anal dysfunction.Hencefactors 
other than radiation needs to be considered towards the reasons for anal 
dysfunction.Anal sphincter should be contoured as organ at risk (OAR) in all 
modern radiation techniques for treating pelvic tumors and the dose volume 
characteristics of anal sphincter to be documented.Symptoms of anal dysfunction 
should be assessed subjectively and objectively. However further prospective 
studies are required in this area for developing guidelines for delineating anal 
sphincter,recommending dose constraint for anal sphincter, and evaluating the 
benefit of sphincter sparing radiation therapy in decreasing late complications in 
rectal cancer survivors. 
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CHRISTIAN MEDICAL COLLEGE, VELLORE  
COORRELATION OF RADIATION DOSE TO ANAL SPHINCTER AND ANAL DYSFUNCTION IN RECTAL 
CANCER PATIENTS UNDERGOING PREOPERATIVE LONG COURSE CHEMORADIATION THERAPY 
 
Case Record Form – 1 
Demographic and Clinical Details 
 
 
 
 ID NO Date of Birth    Hospital Number     Recruitment date  
                               
               dd   mm   yyyy                     dd  mm   yyyy  
 RT No Telephone No          Email]                    
       
                                             
 
 
 
 
 
Last Middle First 
NAME 
 
 
 
 
 
Sex (1=male 2= female) ………………………………………………………… 
 
 
Marital Status (1= unmarried  2= married) ………………………………………. 
 
Occupation  (1=skilled; 2=unskilled)……………………………………………… 
 
Location of 
growth 1.Upper 
2.Middle  
3 Lower ……………………………………………………………………………………. 
 
 
T status (1=T1;2=T2; T3=3; T4=4)…………………………………………………………………… 
 
 
N Status (1=N1; 2=N2; 3= N3) ……………………………………………………………………………. 
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GENERAL EXAMINATION 
 
ECOG Performance status ……………………………………………………………………………….. 
 
0 =Fully active, able to carry on all pre-disease performance without restriction  
1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., 
light house work, office work  
2= Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours 
3= Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours  
4= completely disabled. Cannot carry on any selfcare. Totally confined to bed or 
chair 5= Dead 
 
Height ( in cm) ……………………………………………………………………………………… 
 
Weight ( in Kg) ……………………………………… …………………………………………….. 
 
 
BODY SURFACE AREA (per square metre)…………………………………………………………… 
 
 
Digital Rectal Examination 
 
Colonoscopy 
1.  Growth 
 
Anal manometric pressure 
 
 
Resting pressure (mmHg)  Squeeze pressure (mmHg) 
 
Before radiation therapy 
 
Before surgery 
 
Difference 
 
 
 
 
 
Systemic Examination: 
 
 
Cardiovascular: 
 
 
Respiratory: 
 
 
Gastrointestinal: 
 
 
Neurological: 
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DATE OF BIOPSY : 
 
BIOPSY : 
 
DATE OF STARTING RADIATION THERAPY : 
 
DATE OF COMPLETING RADIATION THERAPY : 
 
BREAK IN RADIATION THERAPY : 
 
NUMBER OF DAYS REASON 
  
  
  
  
 
 
CHEMOTHERAPY USED : 
 
OVERALL TREATMENT TIME : 
 
BREAK IN CHEMOTHERAPY : 
 
NUMBER OF DAYS REASON 
  
  
  
  
 
 
DATE OF SURGERY : 
 
DATE OF LAST FOLLOW UP : 
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ORGAN AT RISKS 
 
   DOSE CONSTRAINT  ACHIEVED 
      
BOWEL BAG     
   V45 < 195 CC    
       
BLADDER  D35% < 45 Gy    
      
FEMORAL HEADS D25% <45 Gy    
   D40%< 40Gy    
       
TARGETS      
      
PTV  ≥ 98% of the PTV receives ≥ 90% of the prescribed dose    
  ≤ 15% of the PTV receives ≥ 105% of the prescribed dose    
  ≤ 10% of the PTV receives ≥ 110% of the prescribed dose    
 
 
RADIATION TECHNIQUE : 
 
 
NUMBER OF FIELDS : 
 
 
PRESCRIBED DOSE TO PTV: 
 
MEAN DOSE TO ANAL SPHINCTER : 
 
LENGTH OF ANAL SPHINCTER 
 
 
 
 
 
V5 V10 V20 V30 V40 V 50 
 
VOL OF ANAL 
SPINCHTER 
RECEIVING 
RADIATION (cc) 
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Volume of Anal sphincter (cc) 
 
 
Distance from midpoint of anal sphincter till inferior border of GTV (in mm) 
 
 
Distance from midpoint of anal sphincter till inferior border of CTV (in mm) 
 
 
Distance from midpoint of anal sphincter till inferior border of PTV (in mm) 
 
 
 
 
 
 
 
 
 
 
Date: __/___/_____ Investigator’s Signature:____________________________ 
 
 
